Menu Search
Equities

Alphatec Holdings Inc

L1Z1:STU

Alphatec Holdings Inc

Actions
  • Price (EUR)9.60
  • Today's Change0.25 / 2.67%
  • Shares traded0.00
  • 1 Year change-9.43%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. The Company is focused on the design, development, and advancement of technology for surgical treatment of spine disorders. It has a range of product portfolios designed to address the spine's various pathologies. Its AIX product platform comprises of its EOS imaging system and VEA alignment mobile application, its SafeOp Neural InformatiX System and Valence. The EOS imaging system is designed to provide calibrated full-body imaging that enables a three-dimensional (3D) model of patients’ skeletal systems. It has developed a patient positioning systems that integrates with its other access systems, providing for a more rigid construct and enhanced reproducibility. It offers procedure-specific access systems, including its Sigma-ALIF Access System, which allows for custom anterior abdominal exposure.

  • Revenue in USD (TTM)572.74m
  • Net income in USD-177.87m
  • Incorporated2005
  • Employees839.00
  • Location
    Alphatec Holdings Inc5818 El Camino RealCARLSBAD 92008United StatesUSA
  • Phone+1 (760) 431-9286
  • Fax+1 (302) 636-5454
  • Websitehttps://atecspine.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.